A Preliminary Study Of Lung Adenocarcinoma Linyi Region Of The EGFR Gene Mutation Status

Objective: Study lung adenocarcinoma in linyi EGFR gene exon 19 and 21 exon mutation status, to explore the relationship between gene mutation and clinical characteristics, provide the basis for clinical.Methods:January 2013- February 2016 Linyi 100 cases of lung adenocarcinoma tissue were analyzed, including 67 males and 33 females. Staged according to the International Lung Cancer Research, 2009 7th edition NSCLC(TNM) staging criteria. Extraction of lung adenocarcinoma DNA, using real-time PCR amplification count using ARMS assay Linyi region of tumor tissue EGFR gene mutations in lung adenocarcinoma patients outside exons 18 to 21. According to the EGFR gene in patients with advanced lung cancer patients with actual test results were given platinum plus paclitaxel regimen of chemotherapy once every three weeks, four cycles of continuous treatment. The data obtained using SPSS 20.0 software for statistical analysis of the relationship between gene mutation status and clinical characteristics of lung adenocarcinoma level EGFR Linyi regions.Results:100 cases of lung cancer patients, 43 cases detected EGFR mutations. Among them, 20 cases of mutation in exon 18(20.0%), 23 cases of mutation in exon 21, accounting for 23.0%. TNM staging of lung cancer Difference 100 cases of lung adenocarcinoma patients with EGFR mutation rate in patients with no significant difference(P> 0.05); lung cancer patients with EGFR mutation rate of gender, smoking history closely related(P <0.05); exon 18 and 21 mutations outside factor mutation in sex, age, smoking history and TNM staging of lung cancer factor difference was not statistically significant(P> 0.05)..Conclusion:Linyi region between lung cancer patients with EGFR gene mutation in exon 19, 21 with the patient’s clinical features more closely related to women, non-smoking patients mutation rate, mutation in exon 19 and exon 21 between the non-mutant Significant differences.